Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm

This publication has 197 references indexed in Scilit:

• Reduction in Renal Relapse and Preservation of Long‐Term Kidney Function After Lupus Low Disease Activity in Patients With Lupus Nephritis
  Arthritis Care & Research, 2025
• Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
  Arthritis & Rheumatism, 2012
• A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
  Arthritis & Rheumatism, 2011
• The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice
  Arthritis & Rheumatism, 2011
• Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
  Arthritis & Rheumatism, 2009
• Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
  Arthritis & Rheumatism, 2008
• Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95
  Arthritis & Rheumatism, 2008
• Induction of interferon‐α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG
  Arthritis & Rheumatism, 2004
• Direct binding of C1q to apoptotic cells and cell blebs induces complement activation
  European Journal of Immunology, 2002
• Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases
  Arthritis & Rheumatism, 2001